GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
NPX-267 overview
NPX-267 is under development for the treatment of non-small cell lung carcinoma (NSCLC), renal cell carcinoma (RCC), colorectal carcinoma (CRC), cholangiocarcinoma (CCA), pancreatic ductal adenocarcinoma (PDAC), urothelial carcinoma (UCC), gastric or gastroesophageal carcinoma, triple-negative breast carcinoma (TNBC), endometrial carcinoma, cervical cancer, osteosarcoma, and prostate cancer. The drug candidate acts by targeting killer cell immunoglobulin like receptor 3DL3 (KIR3DL3) and is administered through intravenous route.
NextPoint Therapeutics overview
NextPoint Therapeutics is a clinical-stage biotechnology company engaged in developing precision oncology therapeutics for the treatment of cancer diseases. The company is headquartered in Cambridge, Massachusetts, the US.
For a complete picture of NPX-267’s drug-specific PTSR and LoA scores, buy the report here.
From 
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.